Shimla Online

Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

 Breaking News
  • No posts were found

Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

August 06
17:00 2020
Chronic Heart Failure Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

“Chronic Heart Failure Pipeline Insight, 2020”

(Albany, NY) Delveinsight has launched a new report on “ Chronic Heart Failure Pipeline Insight, 2020″.


Chronic Heart Failure Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Heart Failure market. A detailed picture of the Chronic Heart Failure pipeline landscape is provided, which includes the disease overview and Chronic Heart Failure treatment guidelines.

The assessment part of the report embraces in-depth Chronic Heart Failure commercial assessment and clinical assessment of the Chronic Heart Failure pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Heart Failure collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Key companies Covered

  • Novartis AG
  • Bayer AG
  • Orion Corp
  • Vifor Pharma Ltd
  • Cytokinetics Inc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • And Many Others


Request for Free Sample Report:


Scope of Report:

  • The Chronic Heart Failure report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chronic Heart Failure across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Chronic Heart Failure therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Chronic Heart Failure research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Heart Failure.


Chronic heart failure, otherwise known as congestive heart failure or heart failure, is an ongoing inability of the heart to pump enough blood through the body to ensure a sufficient supply of oxygen. The causes of the condition vary, but some of the most common risk factors include old age, diabetes, high blood pressure and being overweight. Chronic heart failure is most common in men.

The most common symptoms of chronic heart failure include shortness of breath, tiredness, swelling of the legs and ankles, chest pain and a cough. It most commonly affects older people and people with other heart conditions and is typically treated with a combination of lifestyle and diet changes, and medications. Chronic heart failure is typically a long-term condition that gradually worsens over time. This is the feature that differentiates it from acute heart failure, which develops very suddenly. It cannot typically be cured, but symptoms can be managed effectively.


Request for Free Sample Report:


Key Questions Covered:

  • What are the current options for Chronic Heart Failure treatment?
  • How many companies are developing therapies for the treatment of Chronic Heart Failure
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Chronic Heart Failure?
  • How many Chronic Heart Failure emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Chronic Heart Failure?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Chronic Heart Failure market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Chronic Heart Failure?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Chronic Heart Failure therapies? 
  • What are the clinical studies going on for Chronic Heart Failure and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Chronic Heart Failure
  • How many patents are granted and pending for the emerging therapies for the treatment of Chronic Heart Failure



Table of Contents:

1. Report Introduction

2. Chronic Heart Failure 

2.1. Overview

2.2. History 

2.3. Chronic Heart Failure Symptoms

2.4. Causes


2.6. Chronic Heart Failure Diagnosis 

2.6.1. Diagnostic Guidelines

3. Chronic Heart Failure Current Treatment Patterns

3.1. Chronic Heart Failure Treatment Guidelines

4. Chronic Heart Failure – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Chronic Heart Failure companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Chronic Heart Failure Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Chronic Heart Failure Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Chronic Heart Failure Late Stage Products (Phase-III)

7. Chronic Heart Failure Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Heart Failure Discontinued Products

13. Chronic Heart Failure Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report? 

14. Chronic Heart Failure Key Companies

15. Chronic Heart Failure Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Chronic Heart Failure Unmet Needs

18. Chronic Heart Failure Future Perspectives

19. Chronic Heart Failure Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 


Request for Detailed TOC:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles